Immutep halted its phase III TACTI-004 trial of eftilagimod alfa (IMP-321, “efti”) in first-line non-small-cell lung cancer after an independent data monitoring committee recommended stopping for futility. The interim analysis led to a near-90% collapse in the company’s ASX-listed stock, reflecting the market’s reassessment of efti’s late-stage prospects. CEO Marc Voigt said the company is analyzing the data to determine next steps. The trial readout marks a major setback for a candidate that had shown promise in earlier studies; investigators and investors will scrutinize subgroup data and trial conduct to understand the divergence. Immutep’s outcome also underscores the risk of advancing immunotherapy candidates into large, event-driven registrational trials without broader confirmatory signals. Regulators and partners will be watching for the company’s post-hoc analyses and any planned additional studies, but the immediate commercial and financing implications are acute given Immutep’s market reaction and the centrality of TACTI-004 to its clinical strategy.